Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital

Abstract

Especially CDAD recurrence was associated with excessive costs, which were mostly attributable to a significantly longer overall length of stay. Innovative treatment strategies are warranted to reduce treatment costs and prevent recurrence of CDAD.

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial

“…[2][3][4] Prevention of recurrence of C difficile infection has been identified as a key unmet need. 5 Recurrence is estimated to occur in up to 25% of patients treated with metronidazole or vancomycin, 5,6 is associated with a substantial health-care burden, 6 and is a particular problem in high-risk individuals. 7 Previous administration of antimicrobials typically results in disruption of the colonic microbiota, preceding C difficile colonisation.…”

Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis

“…The current overall economic burden per CDI, addressed as direct treatment costs, has been reported to reach between €7147 and €22,800 [19–21]. However, CDI recurrence is particularly associated with excessive costs, which are mostly attributable to a significantly longer overall length of hospital stay [22]. In a recent German study, direct treatment costs per patient differed significantly: €18,460 in CDI patients without recurrence, €73,900 in patients with recurrent CDI, and €14,530 in controls ( P  < 0.001) [22].…”

“…However, CDI recurrence is particularly associated with excessive costs, which are mostly attributable to a significantly longer overall length of hospital stay [22]. In a recent German study, direct treatment costs per patient differed significantly: €18,460 in CDI patients without recurrence, €73,900 in patients with recurrent CDI, and €14,530 in controls ( P  < 0.001) [22]. The high prevalence of CDI itself also contributes to the economic burden.…”

Stellungnahme der DGVS zum IQWiG-Bericht Nr. 641 Bezlotoxumab (Clostridium-difficile-Infektion) – Nutzenbewertung gemäß §35a SGB V

“…(95 %CI: 14 660 -22 270 €) und für Patienten mit rekurrenter CDI von 73 900 € (95 %CI: 50 340 -97 460 €) im Vergleich zu lediglich 14 530 € bei Kontrollen (95 %CI: 11 730 -17 330 €)[16]. Die Kosten, die mit der Betreuung CDI-Erkrankter verknüpft sind, betrugen in Europa schon vor zehn Jahren mehr als drei Milliarden Euro/Jahr[17].…”